Apellis Pharmaceuticals (APLS) surges 136% premarket on Biogen’s $5.6B acquisition — March 31, 2026
Apellis Pharmaceuticals (NASDAQ: APLS) rocketed 136% in premarket trading on...
Apellis Pharmaceuticals (NASDAQ: APLS) rocketed 136% in premarket trading on...